Homology Medicines Inc
Change company Symbol lookup
Select an option...
FIXX Homology Medicines Inc
APAM Artisan Partners Asset Management Inc
TQQQ ProShares UltraPro QQQ
AVCT American Virtual Cloud Technologies Inc
LITM Snow Lake Resources Ltd
SJ Scienjoy Holding Corp
PBTS Powerbridge Technologies Co Ltd
DRTT DIRTT Environmental Solutions Ltd
LVTX LAVA Therapeutics NV
AGNPF Algernon Pharmaceuticals Inc

Health Care : Biotechnology | Small Cap Blend
Company profile

Homology Medicines, Inc. is a clinical-stage genetic medicines company focused on providing treatment for rare genetic diseases. The Company’s clinical programs include HMI-102, is an investigational gene therapy candidate in clinical development for the treatment of adult patients with phenylketonuria (PKU); HMI-103, which is an investigational gene editing candidate in clinical development for the treatment of patients with PKU, and HMI-203, which is an investigational gene therapy candidate in clinical development for the treatment of patients with mucopolysaccharidosis type II (MPS II), or Hunter syndrome. Additionally, the Company is developing a gene therapy candidate, HMI-104, from its GTx-mAb platform for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH), and conducting research in other diseases, including metachromatic leukodystrophy (MLD). Its platform is designed to utilize human hematopoietic stem cell derived adeno-associated virus vectors.

Closing Price
Day's Change
-0.03 (-1.94%)
B/A Size
Day's High
Day's Low

10-day average volume:

Activision Blizzard reports higher-than-expected sales as Microsoft close awaited

2:29 pm ET August 2, 2022 (MarketWatch)

By Wallace Witkowski

Ahead of earnings, Microsoft reportedly said Activision Blizzard has no 'must have' games

Activision Blizzard Inc. shares ticked higher in the extended session Monday after the videogame publisher released better-than-expected revenue as sales dropped for a third straight quarter.

Activision Blizzard (ATVI) shares declined less than 1% Tuesday after hitting an intraday low of $79.17. The company will not be issuing an earnings presentation or holding a conference call with analysts given Microsoft Corp.'s (MSFT)$69 billion, $95-a-share offer to acquire the publisher that has yet to close. In fact, the highest shares have closed since the offer was announced is $82.31, the closing price after the offer was announced in mid-January. The last time shares closed north of $95 was June 30, 2021.

The company reported second-quarter net income of $280 million, or 36 cents a share, compared with $876 million, or $1.12 a share, in the year-ago period. Activision Blizzard said adjusted earnings, which exclude share-based compensation expenses and other items, were 48 cents a share, down from $1.20 a share in the year-ago period.

Revenue declined to $1.64 billion from $2.3 billion in the year-ago quarter, for the third quarter in a row of declining year-over-year sales. Net bookings fell to $1.64 billion from $1.92 billion last year. Bookings represent the value of digital products and services sold during a quarter, but part of the revenue from those purchases is often recognized in future quarters.

Analysts surveyed by FactSet had forecast earnings of 48 cents a share on revenue of $1.57 billion.

"Even in a challenging economic environment, with so many companies announcing hiring freezes and layoffs, our development headcount grew 25% year-over-year as of the end of the second quarter," said Bobby Kotick, Activision Blizzard's chief executive, in a statement.

"GAAP revenue and EPS declined year over year in the second quarter, and the company expects GAAP revenue and earnings per share to remain lower year over year in the second half of the year," the company said in a statement.

In early July, U.K. regulators opened up an antitrust probe into the deal. The acquisition is scheduled to close at the end of Microsoft's fiscal year ending June 30, 2023. In an odd posturing, Microsoft reportedly told regulators in New Zealand back in June that Activision Blizzard does not produce any "must have" games.

Specifically, the filing stated "with respect to Activision Blizzard videogames, there is nothing unique about the videogames developed and published by Activision Blizzard that is a 'must have' for rival PC and console videogame distributors that could give rise to a foreclosure concern."

Microsoft, however, clarified to MarketWatch after this article was originally published that it values all of Activision Blizzard's games, and that "must have" was a piece of legalese it had to use in the filing.

"'Must have' is a legal term of art and not a statement about the value we place on Activision Blizzard's gaming portfolio," Microsoft said in emailed comments to MarketWatch. "We love every one of their games and have enormous admiration and respect for the creative talent behind them."

Activision Blizzard publishes such games as "Call of Duty" through its Activision label; "World of Warcraft," "Overwatch," and "Diablo" through its Blizzard label; and "Candy Crush" through its King label.

Activision shares are off nearly 5% over the past 12 months, while Microsoft shares are off 2.5%. In comparison, the iShares Expanded Tech-Software Sector ETF (IGV) is down 27%, the S&P 500 index is down 6%, and the tech-heavy Nasdaq Composite Index is down 15%.

-Wallace Witkowski


(END) Dow Jones Newswires

August 02, 2022 14:29 ET (18:29 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.